{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:14Z","timestamp":1793155754781,"version":"4.5.0"},"reference-count":26,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the incorporation of atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, into first-line chemotherapy regimen, survival in patients with extensive-stage small cell lung cancer (ES-SCLC) remains poor. Given the role of dendritic cells (DCs) in modulating responses to anti-programmed cell death protein 1 (PD-1) antibodies, a promising avenue is the development of vaccines based on DCs, together with the evaluation of how DC phenotypic modifications shape treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This is a single-arm, phase Ib\/II, open-label clinical trial investigating the safety and activity of combining autologous tumor lysate pulsed DCs administered intradermally with intravenous atezolizumab as maintenance therapy for patients with ES-SCLC. Following leukapheresis, monocytes were differentiated ex vivo into mature DCs and loaded with irradiated autologous tumor lysate. After standard induction therapy (four cycles of carboplatin, etoposide, and atezolizumab), patients received up to six doses of mature DCs intradermally, along with intravenous atezolizumab 1,200 mg every 3 weeks, until disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      20 patients were enrolled, including six patients with brain metastases. 18 patients received DC vaccination, with a median of three doses (range 1\u20136). Most grade 3\u20134 treatment-related adverse events were hematological and related to chemotherapy. DC vaccination was well tolerated, with only grade 1\u20132 transient skin irritation at the injection site. Among 18 evaluable patients, 17 (94.4%) achieved an objective response. After a median follow-up of 31.4 months, progression-free survival at 2 years (PFS\n                      <jats:sub>2y<\/jats:sub>\n                      ) was 20% (95% CI 6.4% to 39.1%), median overall survival (OS) 11.2 months (95% CI 6.3 to 26.0) and OS\n                      <jats:sub>3y<\/jats:sub>\n                      22.5% (95% CI 6.8% to 43.6%). Six patients achieved long survival (median 30.5 months, range 23.4\u201336.2). Expansion of conventional type DC1 (cDC1s) XCR1\n                      <jats:sup>+<\/jats:sup>\n                      and stem-like progenitor-exhausted (CXCR5\n                      <jats:sup>+<\/jats:sup>\n                      PD-1\n                      <jats:sup>+<\/jats:sup>\n                      ) CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells following chemotherapy plus atezolizumab was associated with improved PFS (HR 0.94, 95% CI 0.90 to 0.99 and HR 0.59, 95% CI 0.39 to 0.89).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DC immunization combined with atezolizumab maintenance following standard chemotherapy plus atezolizumab treatment is well tolerated. Its clinical activity cannot be definitively determined in this study, as it was administered as maintenance therapy; however, the observed rate of long-term survivors suggests a potential benefit. Our findings suggest a pivotal role for cDC1s in mediating the antitumor activity in long-term survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04487756\">NCT04487756<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015351","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:20:21Z","timestamp":1784899221000},"page":"e015351","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04487756","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02840123","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01413295","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-540X","authenticated-orcid":false,"given":"Maria","family":"Gonzalez-Cao","sequence":"first","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sister\u00e9-Or\u00f3","sequence":"additional","affiliation":[{"name":"Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9172-0035","authenticated-orcid":false,"given":"Teresa","family":"Moran","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Cabezon","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital Clinic de Barcelona, FRCB-IDIBAPS, UB, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Aguilar Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Roman","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell and PangaeaOncology Lab, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Molina-Vila","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell and PangaeaOncology Lab, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-5566","authenticated-orcid":false,"given":"K\u00fcr\u015fat","family":"Birgin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domenjo-Vila","sequence":"additional","affiliation":[{"name":"Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Piqu\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[{"name":"Apheresis Unit, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Charry","sequence":"additional","affiliation":[{"name":"Apheresis Unit, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Reyes","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"},{"name":"Instituto Oncologico Dr Rosell, Quir\u00f3n Teknon Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Moya","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"},{"name":"Instituto Oncologico Dr Rosell, Hospital Universitari General de Catalunya, Sant Cugat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Cirera","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Hospital Universitari Sagrat Cor, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Esparre","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Drozdowskyj","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-976X","authenticated-orcid":false,"given":"Elizabeth","family":"Mart\u00ednez P\u00e9rez","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell and PangaeaOncology Lab, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[{"name":"Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-1648","authenticated-orcid":false,"given":"Manel","family":"Juan","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital Clinic de Barcelona, FRCB-IDIBAPS, UB, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-5317","authenticated-orcid":false,"given":"Andreas","family":"Meyerhans","sequence":"additional","affiliation":[{"name":"Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain"},{"name":"ICREA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Benitez-Ribas","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital Clinic de Barcelona, FRCB-IDIBAPS, UB, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072406201262000_14.7.e015351.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"2026072406201262000_14.7.e015351.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107924"},{"key":"2026072406201262000_14.7.e015351.3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"2026072406201262000_14.7.e015351.4","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) . Clinical review \u2013 durvalumab (Imfinzi) for extensive-stage small-cell lung cancer. Ottawa: CADTH, 2021."},{"key":"2026072406201262000_14.7.e015351.5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026072406201262000_14.7.e015351.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620374","article-title":"Dendritic Cell-Based Immunotherapy in Lung Cancer","volume":"11","author":"Stevens","year":"2020","journal-title":"Front Immunol"},{"key":"2026072406201262000_14.7.e015351.7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41590-026-02419-4","article-title":"Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes","volume":"27","author":"Lai","year":"2026","journal-title":"Nat Immunol"},{"key":"2026072406201262000_14.7.e015351.8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","article-title":"The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma","volume":"13","author":"Gobbini","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026072406201262000_14.7.e015351.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.05.006"},{"key":"2026072406201262000_14.7.e015351.10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","volume":"13","author":"Zhu","year":"2023","journal-title":"J Pharm Anal"},{"key":"2026072406201262000_14.7.e015351.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026072406201262000_14.7.e015351.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112123"},{"key":"2026072406201262000_14.7.e015351.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1353889","article-title":"Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis","volume":"15","author":"Bonanno","year":"2024","journal-title":"Front Immunol"},{"key":"2026072406201262000_14.7.e015351.14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4143\/crt.2023.913","article-title":"The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study","volume":"56","author":"Choi","year":"2024","journal-title":"Cancer Res Treat"},{"key":"2026072406201262000_14.7.e015351.15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00262-022-03283-5","article-title":"A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study","volume":"72","author":"Espa\u00f1ol-Rego","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026072406201262000_14.7.e015351.16","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.484801"},{"key":"2026072406201262000_14.7.e015351.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2013"},{"key":"2026072406201262000_14.7.e015351.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003"},{"key":"2026072406201262000_14.7.e015351.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012"},{"key":"2026072406201262000_14.7.e015351.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00726-4"},{"key":"2026072406201262000_14.7.e015351.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80149-1"},{"key":"2026072406201262000_14.7.e015351.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.08.006"},{"key":"2026072406201262000_14.7.e015351.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.019"},{"key":"2026072406201262000_14.7.e015351.24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/08820139.2013.871555","article-title":"Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody","volume":"43","author":"Kobie","year":"2014","journal-title":"Immunol Invest"},{"key":"2026072406201262000_14.7.e015351.25","first-page":"56","article-title":"Migration of human dendritic cells after injection in patients with metastatic malignancies","volume":"59","author":"Morse","year":"1999","journal-title":"Cancer Res"},{"key":"2026072406201262000_14.7.e015351.26","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20250099","article-title":"pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection","volume":"223","author":"Hern\u00e1ndez-Garc\u00eda","year":"2026","journal-title":"J Exp Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:20:25Z","timestamp":1784899225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,24]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2026-015351"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015351","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}